01.05.26 -- Is 2026 The Year We End The "Culture Wars" Between Sponsors And CDMOs?

Bioanalysis service quality significantly impacts project success. Don't settle for typical CRO claims; demand better technology, pricing transparency, and dedicated partnership.

A robust formulation development approach integrates scientific principles, systematic development, and preclinical models to facilitate early identification of candidates with poor developability.

With these four steps to successful biologic process development, it is possible to mitigate risk, manufacture a high-quality product, and increase the efficiency of your timeline to patients.

Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

Ensure the potency and efficacy of your biologic products with a GMP-compliant potency bioassay, offering accurate real-time assessments for GMP release and stability testing.

For emerging biotechs looking to refine their development processes and boost their chances of commercial success, exploring these partnership opportunities could prove invaluable.

See some of the key considerations in cell line development, how advances in technology are improving the efficiency and productivity of cell lines, and the future of cell line development.

Automated manufacturing is a powerful but often misunderstood tool available to produce drug delivery and other pharmaceutical devices — whether established designs or innovative new ideas.

The pre-filled syringe space is a fast growing pharma sector, offering greater patient safety and lower manufacturing costs. Pre-filled doesn't mean easy to fill — specific challenges still need to be addressed.

Learn how an approach with modular N-1 perfusion strategies shortens seed train timelines and reduces facility strain — enabling upstream processes that scale reliably for commercial manufacturing.

A network of 9 sites in 5 countries supports NCE programs from discovery through commercialization, offering API capabilities and a cost-neutral model for streamlined outsourcing.

Leverage robust development strategies and enable an optimized process for mAb development and manufacturing, efficiency and speed with exceptional quality, and high titers with lower-cost workflows.

Biopharmaceutical development hinges on a robust CMC strategy. Discover how our expertise allows us to collaboratively design the optimal suite of analytical studies tailored to your specific molecule.

With proven expertise in process development, optimization, and CGMP manufacturing, Avid offers end-to-end CDMO solutions backed by flexible capacity designed to scale with program needs.